Background: Mpox is a viral zoonosis that has gained increased attention due to a global outbreak in 2022, significantly impacting men who have sex with men (MSM). Vaccination for this disease poses a public health challenge; because it carries a strong stigma, there may be greater hesitancy in vulnerable groups. Objectives: This study aimed to determine the prevalence and factors associated with Mpox vaccine hesitancy among Brazilian MSM. Methods: A cross-sectional study was conducted between September and December 2022 using an online survey targeted at MSM. Recruitment was carried out through social media and dating apps. The sample consisted of 1449 participants and the analysis involved bivariate logistic regression. Results: The prevalence of Mpox vaccine hesitancy was 7.57%. The significant factors associated with hesitancy were primarily related to sexual practices and attitudes towards Mpox exposure and diagnosis, such as not using “glory holes” (aOR: 19.82; 95% CI: 1.60–245.69), reluctance to undergo pre- and post-exposure testing for Mpox (aOR: 9.54; 95% CI: 5.52–16.48), and not knowing close contacts diagnosed with Mpox (aOR: 4.09; 95% CI: 1.72–9.73). Participants who would not take precautions after diagnosis (aOR: 3.00; 95% CI: 1.27–7.07) and those who would not disclose their serological status (aOR: 1.93; 95% CI: 1.13–3.30) also showed a higher likelihood of vaccine hesitancy. Conclusion: Public health strategies should address these factors to expand knowledge about vaccination barriers, plan educational campaigns with targeted messaging for the MSM population, and provide inclusive healthcare environments to increase vaccine acceptance and reduce Mpox transmission in vulnerable groups.

Background: Chemsex, defined as the intentional use of psychoactive substances to enhance sexual experiences, is associated with increased risk of sexually transmitted infections (STIs), mental health harms, and disruptions in continuity of care, particularly among men who have sex with men. In Brazil, health services lack an integrated, stigma-sensitive care pathway (CP) for prevention, clinical management, and harm reduction. Embedding a CP within the Health Care Network (HCN) is essential to organize access, continuity, and quality of care. Objective: This study aims to develop an evidence-informed CP for people who engage in chemsex, grounded in the needs of users, managers, and health professionals within the HCN, and supported by educational tools and implementation strategies. Methods: This sequential multimethod study is guided by the Knowledge-to-Action framework. Phase 1 (predevelopment) focuses on establishing partnerships and mapping the local context. Phase 2 (Knowledge Creation) includes (1) cross-sectional surveys with adults from the general population (target n≈1600) to estimate chemsex prevalence and associated factors, and with managers (n≈54) and health professionals (n≈135) to assess knowledge, attitudes, practices, barriers, and stigma; (2) a scoping review following established methodological guidelines; and (3) triangulation and concept mapping to integrate quantitative and qualitative findings. Data will be collected via REDCap (Research Electronic Data Capture), online and in person, during testing events. Quantitative analyses will involve descriptive statistics and regression models. Interviews and focus groups will undergo thematic analysis supported by Nvivo software. Educational products will be developed and evaluated for appearance, content, and usability by experts using a content validity index ≥0.78 as a cutoff. Phase 3 (Action Cycle) includes adapting knowledge to the local context, co-designing and validating the CP with stakeholders, piloting implementation in priority municipalities, and establishing monitoring processes. Process indicators (eg, number of trained professionals, educational activities, rapid tests performed, and app engagement) and outcome indicators (eg, STI testing and linkage to care, service use across the HCN) will be monitored through official information systems. Results: Ethical approval was obtained in April 2025. Recruitment and data collection began in June 2025 through online and in-person strategies. By December 2025, 3061 individuals had been screened online, and 1723 participants had undergone rapid testing for STIs. Data collection is expected to conclude by June 2026, followed by data cleaning and preliminary analyses between April and June 2026, inferential and qualitative analyses between July and September 2026, and CP development and validation between October and December 2026. Conclusions: This protocol will generate a CP tailored to chemsex and validated educational resources to support harm reduction, mental health, and STI prevention within the HCN. Findings are expected to inform inclusive policies, reduce stigma, and strengthen care coordination within Brazil’s Unified Health System. International Registered Report Identifier (IRRID): DERR1-10.2196/84068

The COVID-19 pandemic has disrupted healthcare services and intensified socio-economic vulnerabilities, potentially escalating harmful substance use. In Brazil, pre-pandemic mortality from alcohol and drug use was stable. However, the pandemic introduced new risks that may have triggered a significant increase in related deaths. This study, therefore, aims to assess the impact of the COVID-19 pandemic on alcohol- and drug-related deaths in Brazil from 2020 to 2022. This population-based ecological study analyzed alcohol- and drug-related mortality across Brazil from 2015 to 2022 using data from the Brazilian Mortality Information System (SIM). Temporal trends were examined using Joinpoint regression, while interrupted time-series analyses assessed deviations post-pandemic onset. Spatial variations were visualized using choropleth maps. Alcohol- and drug-related mortality increased by 18.3% in 2020, 22.4% in 2021, and 26.0% in 2022. The Northeast (2020 = 24.9%; 2021 = 24.0%; 2022 = 31.8%), Southeast (2020 = 18.2%; 2021 = 24.3%; 2022 = 21.0%), and South (2020 = 13.1%; 2021 = 23.6%; 2022 = 35.2%) regions recorded the highest increases, with most states showing significant growth in deaths. We also observed an increase in mortality associated with the use of Psychoactive substances (PAS) in both sexes (male: average annual percentage changes (AAPCs) = 3.6%; female: AAPC = 4.6%), individuals aged 20 to 39 (AAPC = 2.0%), and those aged 60 and above (AAPC = 1.8%). Interrupted time-series analyses confirmed a marked and statistically significant increase in mortality post-March 2020. The findings suggest a collateral epidemic of substance-related deaths fueled by the COVID-19 pandemic's disruptions to harm reduction services, treatment access, and socio-economic stability. These results underscore the urgent need to enhance healthcare systems, reinforce harm reduction services, and develop intersectoral policies targeting social inequalities to mitigate future crises. This research is part of the PEGA@ACAO study and was funded by the São Paulo Research Foundation (FAPESP, grant #2024/15320-5 and #2025/04763-6); the National Council for Scientific and Technological Development (CNPq, grant #405741/2024-3); and the Coordination for the Improvement of Higher Education Personnel (CAPES, finance code #001).

Adult entertainment work may be associated with increased vulnerability to sexually transmitted infections, particularly HIV. In Brazil, pre-exposure prophylaxis (PrEP) for HIV infection has been available through the Brazilian Unified Health System (SUS) since November 2017, representing a significant advancement in public sexual health policy. The objective of this study was to understand the individual and social determinants that promote PrEP use among adult entertainment workers. This was a cross-sectional, analytical, and quantitative study. A multivariate modeling approach was employed to identify factors independently associated with PrEP use. The study included 254 adult entertainment workers using oral PrEP through the SUS, predominantly young adults (141; 55.5%), SUS users (248; 97.6%), single (213; 83.9%), non-white (142; 55.9%), cisgender (148; 58.3%), and heterosexual (152; 59.8%). Factors independently associated with greater PrEP use included having adult entertainment as the main source of income (aPR: 2.69; 95% CI: 1.86–3.95), prior use of PEP (aPR: 2.49; 95% CI: 1.63–3.81), undergoing any type of health treatment (aPR: 1.56; 95% CI: 1.15–2.12), and having a history of STIs (aPR: 1.51; 95% CI: 1.10–2.08). Conclusion: PrEP use in this population was strongly influenced by structural and contextual factors, indicating that the availability of the technology alone does not ensure its effectiveness.

Background: Chemsex, the intentional use of psychoactive substances to enhance sexual experiences, is an emerging public health issue in Brazil, associated with increased risks of sexually transmitted infections and complex psychosocial vulnerabilities. Despite the universal coverage provided by the Unified Health System (SUS), individuals who practice chemsex often encounter barriers to healthcare, including stigma, discrimination, and a lack of specialized services. To date, no comprehensive reviews appear to synthesize evidence on how this population accesses healthcare in the Brazilian context; existing knowledge remains fragmented across individual studies. Objectives: The aim is to map and synthesize the available evidence regarding access to health services among people who engage in chemsex in Brazil, identifying health needs, professional demands, barriers, and facilitators. Methods: The protocol follows the Joanna Briggs Institute methodology for scoping reviews and PRISMA-ScR guidelines. A systematic search will be conducted in MEDLINE (PubMed), Embase, Scopus, SciELO, and LILACS for studies published between 2014 and 2024 in Portuguese, English, or Spanish. Data will be summarized using descriptive and narrative synthesis, presented in tables and thematic categories. Studies will be included if they address chemsex or sexualized drug use in Brazil and report on healthcare access, regardless of gender identity, sexual orientation, or drug type. Studies that do not address chemsex, focus on drug use outside a sexual context, or are unrelated to Brazil will be excluded. Expected results: The review is expected to identify key barriers and facilitators to healthcare access, highlight knowledge gaps for underrepresented groups, and support recommendations for research, policy, and practice to improve care for people engaging in chemsex in Brazil. By focusing on an underexplored intersection of drug use, sexuality, and healthcare access in Latin America, this study aims to provide an innovative contribution to public health literature.

Background/Objectives: Sexualized drug use (SDU) and chemsex have emerged as a growing public health concern globally, reflecting complex intersections between sexual practices, psychoactive substance use, and structural vulnerabilities. In Brazil, however, evidence on healthcare access among individuals who engage in SDU/chemsex remains limited and fragmented. This scoping review aimed to map and analyze the available literature on healthcare access in this population, identifying barriers, facilitators, and gaps in care. Methods: The review followed the Arksey and O’Malley framework and Joanna Briggs Institute recommendations, with searches conducted in six databases (MEDLINE/PubMed, Embase, Scopus, SciELO, LILACS, and PsycINFO) for studies published between 2014 and 2025. Results: Eleven studies met the inclusion criteria, predominantly quantitative and concentrated in large urban centers. Findings indicate that healthcare access is shaped by persistent structural and symbolic barriers, including stigma, discrimination, fear of disclosure, and limited professional preparedness. Care remains largely centered on human immunodeficiency virus (HIV) and sexually transmitted infections (STIs) services, with insufficient integration of primary care, mental health, and substance use services, contributing to fragmented care. Significant gaps were identified, including the underrepresentation of women, transgender, and non-binary populations, and the absence of studies focusing on healthcare professionals. Conclusions: Substance use patterns reflect both global trends and local specificities, particularly the prominence of alcohol and cocaine in Brazil. This review provides the first synthesis of Brazilian evidence on chemsex from a healthcare access perspective. The findings highlight critical inequities and support the need for integrated, stigma-free, and context-sensitive care within the Brazilian Unified Health System. Based on these findings, the VIP-SDU/Chemsex Model is proposed as a multilevel framework to explain how structural, symbolic, and programmatic factors shape access and health outcomes.